Plain-English translation of NCT07239570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a personalized approach to treating chronic kidney disease using three medications: , , and . Instead of giving all patients the same treatment, doctors will choose which medication to start based on your individual characteristics and kidney markers, then adjust your treatment plan based on how your kidneys respond over time.
Most kidney disease patients receive the same standard treatment, but people respond differently to medications. This trial is testing whether a personalized approach—where treatment is matched to your specific kidney markers and adjusted as you improve—might work better than one-size-fits-all care.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive personalized treatment or standard care. If assigned to personalized treatment, you will start with one medication at the highest dose you can tolerate. After about four weeks, your kidney markers will be tested, and based on those results, your doctor will decide whether to continue, switch, or add another medication. This process repeats up to three times over several months as your treatment is tailored to your individual response.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Denmark
Germany
Spain
Sweden